Browsing Academic by Subject "Ibrutinib"
Now showing items 1-2 of 2
-
Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy
( Marshfield Clinic , 2022 , Article)Objective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in ... -
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia Case report and literature review
( SAGE Publications Ltd , 2019 , Article)Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed ...